Genmab A/S announced it is terminating clinical development of acasunlimab, a bispecific antibody formerly partnered with BioNTech. The Danish developer said it will stop work on the asset after BioNTech exited the program last year and Genmab evaluated strategic options. Acasunlimab targeted a dual mechanism and was being developed for oncology indications; Genmab’s decision follows partner withdrawal and an internal reassessment of resources. The company will wind down the program activities and reallocate assets to higher-priority candidates. Investors and competitors will note the program cut as an example of portfolio pruning when complex bispecific programs face technical or commercial uncertainty. Genmab said it will continue to evaluate its pipeline and focus on assets with clearer development paths.